Hurley Capital’s ClearPoint Neuro CLPT Stock Holding History

Hurley Capital’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.89K	Hold	330	–	–	﹤0.01%	399
2026 Q1	$3K	Hold	330	–	–	﹤0.01%	528
2025 Q4	$4.51K	Buy	+330	New	+$6.12K	﹤0.01%	435

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Hurley Capital's CLPT Position: Q2 2026 in Review

Hurley Capital held its ClearPoint Neuro (CLPT) position steady in Q2 2026 at 330 shares worth $5.89K. The position accounts for ﹤0.01% of the portfolio, ranked #399.

Hurley Capital first reported a position in CLPT in Q4 2025 and has held it in 3 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Hurley Capital held 330 shares of ClearPoint Neuro worth $5.89K as of Q2 2026.
Hurley Capital left its ClearPoint Neuro share count unchanged in Q2 2026.
ClearPoint Neuro made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #399 holding.
Hurley Capital first reported a position in ClearPoint Neuro in Q4 2025 and has held it in 3 quarters since.
129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.